实体瘤新型细胞疗法集中化的影响——面向欧洲的卫生系统规划模型
该研究基于英国国家医疗服务体系(NHS)2016至2018年间139家医院收治的10050例转移性结直肠癌接受全身治疗的患者,构建七种细胞疗法服务集中化情景模型,评估其对出行时间、公平性和医院容量的影响。结果显示每种集中化情景均使预测出行时间增加3倍,集中至综合癌症中心(情景A)影响最小(额外增加40.9分钟),72%患者仍可在1小时内到达专科服务;集中至现有CAR-T中心(情景D)则导致44%患者无法在1小时内到达设施。五种情景下额外出行负担对低社会经济群体影响不成比例。
要点
- 每种集中化情景均使预测出行时间增加3倍。
- 集中至综合癌症中心(情景A)额外出行时间最小,为40.9分钟,72%患者仍在1小时内可达。
- 集中至现有CAR-T中心(情景D)导致44%患者无法在1小时内到达设施。
核心结论
- 欧洲实体瘤细胞疗法服务的本地化需要在可及性、公平性和临床安全性之间取得平衡。
- 该建模方法可用于所有欧洲卫生系统,以了解集中化实施前的影响,为优化服务设计和缓解措施提供信息。
研究设计与样本
- 基于全国人群的研究,纳入2016年至2018年间139家NHS医院中接受全身治疗的10050例转移性结直肠癌患者。
- 设定七种假设情景A至G,将细胞疗法服务集中至15至51个中心,例如情景A集中至51个综合癌症中心,情景D集中至15个CAR-T中心。
- 基于患者偏好使用条件逻辑回归模型将患者重新分配至指定专科中心;使用地理信息系统计算出行时间;使用多变量线性回归模型估计出行负担在不同人口学特征间的差异。
主要发现
- 每种集中化情景均使预测出行时间增加3倍。
- 集中至综合癌症中心(情景A)对出行时间影响最小,额外增加40.9分钟,72%患者仍可在1小时内到达专科服务。
- 集中至现有CAR-T中心(情景D)导致44%患者无法在1小时内到达设施。
- 五种情景下额外出行负担对低社会经济群体影响不成比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrating cell therapies for solid cancers requires centralising services to ensure high quality and poses unique challenges for all healthcare systems. In this national population-based study, we modelled the effect of different centralisation scenarios in the English NHS on travel times, equity and hospital capacity as an archetype to inform European planning. METHODS: We identified 10,050 patients treated with systemic therapy for metastatic colorectal cancer in 139 NHS hospitals between 2016 and 2018. Seven hypothetical scenarios A-G centralised cell therapy services to between 15 and 51 centres. For example to A) 51 comprehensive cancer centres; or D) 15 CAR-T centres. For each scenario reallocation of patients to the designated specialist centre was based on patient preferences using conditional logistic regression models; travel times were calculated using a geographic information system; multivariable linear regression models estimated the variation in travel burden across demographic characteristics. KEY FINDINGS: For each centralisation scenario there was a 3 times increase in predicted travel time. Centralising services to comprehensive cancer centres (scenario A) had the smallest impact on travel time (additional 40.9 min); 72 % of patients remained within 1 h of specialist services. Centralisation to existing CAR-T centres (scenario D) resulted in 44 % of patients not having access to a facility within 1 h. For 5 scenarios additional travel burden disproportionately affected low socioeconomic groups. CONCLUSIONS: Localisation of solid cancer cell therapy services in Europe requires a balance between access, equity, and clinical safety. This modelling approach can be used in all European health systems, to understand the pre-implementation impact of centralisation to inform optimum service design and mitigations.
引用
- Han L, Josephs D, McDonald L, et al. The effect of centralising novel cell therapies for solid cancers - a health systems planning model for Europe. Eur J Cancer. 2025. PMID: 40633200. doi:10.1016/j.ejca.2025.115594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。